title: [Prostate cancer screening: an update].
abstract: Prostate cancer screening using PSA is controversial because of a low specificity and detection of non clinically relevant cancer. Two important studies have been published recently. One of two studies suggests a 20% lowering in specific prostate cancer mortality due to PSA screening. This benefit is relevant but implies at a high risk of overtreatment and treatment-related complications. Currently PSA screening is only proposed as an individual screening for informed patients.
authors.affiliation: Service d'urologie, CHUV, Lausanne.
authors.forename: T
authors.initials: T
authors.lastname: Tawadros
authors.forename: A
authors.initials: A
authors.lastname: Doerfler
authors.forename: C
authors.initials: C
authors.lastname: Treuthardt
authors.forename: V
authors.initials: V
authors.lastname: Praz
authors.forename: F
authors.initials: F
authors.lastname: Levi
authors.forename: A
authors.initials: A
authors.lastname: Zouhair
authors.forename: D
authors.initials: D
authors.lastname: Berthold
authors.forename: J
authors.initials: J
authors.lastname: Bauer
authors.forename: C
authors.initials: C
authors.lastname: Iselin
authors.forename: P
authors.initials: P
authors.lastname: Jichlinski
mesh_terms: D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*
chemical_list: D017430:Prostate-Specific Antigen